DOCSLIB.ORG

Abacavir Tablets USP 300 Mg Front Side Printing Page 1 of 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abacavir Tablets USP 300 Mg Front Side Printing Page 1 of 2 7822 7822 HIGHLIGHTS OF PRESCRIBING INFORMATION • Pediatric Patients Aged 3 Months and Older: • Before starting abacavir, review medical history for prior exposure to any abacavir-containing product. Table 4. Laboratory Abnormalities (Grades 3-4) in Therapy-naive Adults (CNA30024) through 48 Weeks MEDICATION GUIDE These highlights do not include all the information Administered either once or twice daily. Dose NEVER restart abacavir or any other abacavir-containing product following a hypersensitivity reaction to of Treatment should be calculated on body weight (kg) and abacavir, regardless of HLA-B*5701 status. needed to use ABACAVIR TABLETS safely and Abacavir plus Zidovudine plus should not exceed 600 mg daily. (2.3) • To reduce the risk of a life-threatening hypersensitivity reaction, regardless of HLA-B*5701 status, Grade 3/4 Abacavir tablets USP 300 mg effectively. See full prescribing information for Lamivudine plus Efavirenz Lamivudine plus Efavirenz • Patients with Hepatic Impairment: Mild hepatic discontinue abacavir immediately if a hypersensitivity reaction is suspected, even when other diagnoses Laboratory Abnormalities ABACAVIR TABLETS. (n=324) (n=325) (A bak a vir) impairment – 200 mg twice daily. (2.4) are possible (e.g., acute onset respiratory diseases such as pneumonia, bronchitis, pharyngitis, or ′ ABACAVIR tablets, for oral use influenza; gastroenteritis; or reactions to other medications). Elevated CPK (>4 X ULN) 8% 8% -----------DOSAGE FORMS AND STRENGTHS--------- Initial U.S. Approval 1998 • If a hypersensitivity reaction cannot be ruled out, do not restart abacavir or any other abacavir containing Elevated ALT (>5 X ULN) 6% 6% What is the most important information I should know about abacavir • Tablets: 300 mg scored (3) products because more severe symptoms which may include life-threatening hypotension and death can WARNING: HYPERSENSITIVITY REACTIONS Elevated AST (>5 X ULN) 6% 5% tablets? occur within hours. See full prescribing information for complete ----------------CONTRAINDICATIONS------------------ • If a hypersensitivity reaction is ruled out, patients may restart abacavir. Rarely, patients who have stopped Hypertriglyceridemia(>750 mg/dL) 6% 5% Abacavir tablets can cause serious side effects, including: boxed warning. • Presence of HLA-B*5701 allele. (4) abacavir for reasons other than symptoms of hypersensitivity have also experienced life-threatening • Serious and sometimes fatal hypersensitivity • Prior hypersensitivity reaction to abacavir. (4) Hyperamylasemia (>2 X ULN) 4% 5% • Serious allergic reaction (hypersensitivity reaction) that can reactions within hours of reinitiating abacavir therapy. Therefore, reintroduction of abacavir or any other reactions have occurred with abacavir • Moderate or severe hepatic impairment. (4) Neutropenia (ANC <750/mm3) 2% 4% abacavir-containing product is recommended only if medical care can be readily accessed. cause death have happened with abacavir tablets and other tablets 300 mg. (5.1) -----------WARNINGS AND PRECAUTIONS------------ • A Medication Guide and Warning Card that provide information about recognition of hypersensitivity Anemia (Hgb ≤ 6.9 gm/dL) <1% 2% • Hypersensitivity to abacavir is a multi- abacavir-containing products. Your risk of this allergic reaction is • Lactic acidosis and severe hepatomegaly with reactions should be dispensed with each new prescription and refill. 3 organ clinical syndrome. (5.1) Thrombocytopenia (Platelets < 50,000/ mm ) 1% <1% * steatosis, including fatal cases, have been much higher if you have a gene variation called HLA-B 5701. • Patients who carry the HLA-B*5701 allele 5.2 Lactic Acidosis and Severe Hepatomegaly with Steatosis Leukopenia (WBC ≤ 1,500/mm3) <1% 2% reported with the use of nucleoside analogues. are at higher risk for experiencing a Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of Your healthcare provider can determine with a blood test if you have (5.2) ULN = Upper limit of normal. hypersensitivity reaction to abacavir. (5.1) nucleoside analogues, including abacavir. A majority of these cases have been in women. Female sex and obesity • Immune reconstitution syndrome has been this gene variation. • Abacavir is contraindicated in patients may be risk factors for the development of lactic acidosis and severe hepatomegaly with steatosis in patients n = Number of subjects assessed. reported in patients treated with combination with a prior hypersensitivity reaction to treated with antiretroviral nucleoside analogues. Treatment with Abacavir tablets should be suspended in any antiretroviral therapy. (5.3) Laboratory abnormalities in CNA3005 are listed in Table 5. If you get a symptom from 2 or more of the following groups while abacavir and in HLA-B*5701-positive patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity, taking abacavir tablets, call your healthcare provider right away to patients. (4) ------------------ADVERSE REACTIONS----------------- which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations. Table 5. Treatment-emergent Laboratory Abnormalities (Grades 3-4) in CNA3005 • Discontinue abacavir tablets 300 mg as • The most commonly reported adverse Abacavir plus Lamivudine/ Indinavir plus Lamivudine/ find out if you should stop taking Abacavir tablets. 5.3 Immune Reconstitution Syndrome soon as a hypersensitivity reaction is reactions of at least moderate intensity Grade 3/4 Laboratory Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, Zidovudine Zidovudine suspected. Regardless of HLA-B*5701 (incidence greater than or equal to 10%) in adult Abnormalities Symptom(s) including abacavir. During the initial phase of combination antiretroviral treatment, patients whose immune (n=262) (n=264) status, permanently discontinue abacavir HIV-1 clinical trials were nausea, headache, systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such Elevated CPK (>4 x ULN) 18 (7%) 18 (7%) tablets 300 mg if hypersensitivity cannot be malaise and fatigue, nausea and vomiting, Group 1 Fever as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), 7822 ruled out, even when other diagnoses are and dreams/sleep disorders. (6.1) ALT (>5.0 x ULN) 16 (6%) 16 (6%) possible. (5.1) which may necessitate further evaluation and treatment. Group 2 Rash • The most commonly reported adverse Neutropenia (<750/mm3) 13 (5%) 13 (5%) • Following a hypersensitivity reaction to reactions of at least moderate intensity Autoimmune disorders ( such as Graves’ disease, polymyositis, and Guillain- Barré syndrome) have also been Group 3 Nausea, vomiting, diarrhea, abdominal (stomach area) pain abacavir, NEVER restart abacavir tablets (incidence greater than or equal to 5%) in reported to occur in the setting of immune reconstitution, however, the time to onset is more variable and can Hypertriglyceridemia (>750 mg/dL) 5 (2%) 3 (1%) 300 mg or any other abacavir-containing pediatric HIV-1 clinical trials were fever and/or occur many months after initiation of treatment. Hyperamylasemia (>2.0 x ULN) 5 (2%) 1 (<1%) Group 4 Generally ill feeling, extreme tiredness, or achiness product. (5.1) chills, nausea and vomiting, skin rashes, and Hyperglycemia (>13.9 mmol/L) 2 (<1%) 2 (<1%) Group 5 Shortness of breath, cough, sore throat ear/nose/throat infections. (6.2) 5.4 Myocardial Infarction ------------RECENT MAJOR CHANGES----------------- Several prospective, observational, epidemiological studies have reported an association with the use of Anemia (Hgb ≤6.9 g/dL) 0 (0%) 3 (1%) Boxed Warning To report SUSPECTED ADVERSE REACTIONS, abacavir and the risk of myocardial infarction (MI). Meta-analyses of randomized, controlled, clinical trials have A list of these symptoms is on the Warning Card your pharmacist gives you. Warnings and Precautions, Lactic Acidosis and Severe contact Strides Pharma Inc. at 1-877-244-9825 observed no excess risk of MI in abacavir-treated subjects as compared with control subjects. To date, there ULN = Upper limit of normal. or www.strides.com or FDA at 1-800-FDA-1088 or Hepatomegaly with Steatosis (5.2) 05/2018 is no established biological mechanism to explain a potential increase in risk. In totality, the available data from n = Number of subjects assessed. Carry this Warning Card with you at all times. Warnings and Precautions, Fat Redistribution www.fda.gov/medwatch. the observational studies and from controlled clinical trials show inconsistency; therefore, evidence for a causal The frequencies of treatment-emergent laboratory abnormalities were comparable between treatment groups (previous 5.4) Removed 05/2018 relationship between abacavir treatment and the risk of MI is inconclusive If you stop abacavir tablets because of an allergic reaction, never -----------------DRUG INTERACTIONS------------------ Warnings and Precautions, Myocardial Infarction (5.4) in CNA30021. • Methadone: An increased methadone dose may As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral take abacavir tablets or any other abacavir-containing medicine 05/2018 be required in a small number of patients. (7.1) therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, 6.2 Clinical Trials Experience
Load more

Recommended publications
  • TRIZIVIR® (Abacavir Sulfate, Lamivudine, and Zidovudine) Tablets
    NDA 21-205/S-011 Page 4 PRESCRIBING INFORMATION TRIZIVIR® (abacavir sulfate, lamivudine, and zidovudine) Tablets WARNINGS TRIZIVIR contains 3 nucleoside analogues (abacavir sulfate, lamivudine, and zidovudine) and is intended only for patients whose regimen would otherwise include these 3 components. Hypersensitivity Reactions: Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir sulfate, a component of TRIZIVIR. Hypersensitivity to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: (1) fever, (2) rash, (3) gastrointestinal (including nausea, vomiting, diarrhea, or abdominal pain), (4) constitutional (including generalized malaise, fatigue, or achiness), and (5) respiratory (including dyspnea, cough, or pharyngitis). Discontinue TRIZIVIR as soon as a hypersensitivity reaction is suspected. Permanently discontinue TRIZIVIR if hypersensitivity cannot be ruled out, even when other diagnoses are possible. Following a hypersensitivity reaction to abacavir, NEVER restart TRIZIVIR or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death. Reintroduction of TRIZIVIR or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of hypersensitivity to abacavir therapy, can result in serious or fatal hypersensitivity reactions. Such reactions can occur within hours (see WARNINGS and PRECAUTIONS: Information
    [Show full text]
  • ZIAGEN Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Patients With Hepatic Impairment: Mild hepatic impairment – 200 mg These highlights do not include all the information needed to use twice daily; moderate/severe hepatic impairment – contraindicated. (2.3) ZIAGEN safely and effectively. See full prescribing information for --------------------- DOSAGE FORMS AND STRENGTHS -------------- ZIAGEN. Tablets: 300 mg; Oral Solution: 20 mg/mL (3) ZIAGEN® (abacavir sulfate) Tablets and Oral Solution -------------------------------CONTRAINDICATIONS------------------------ Initial U.S. Approval: 1998 • Previously demonstrated hypersensitivity to abacavir. (4, 5.1) • Moderate or severe hepatic impairment. (4) WARNING: HYPERSENSITIVITY REACTIONS/LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY ----------------------- WARNINGS AND PRECAUTIONS ---------------- • Hypersensitivity: Serious and sometime fatal hypersensitivity reactions See full prescribing information for complete boxed warning. have been associated with ZIAGEN and other abacavir-containing • Serious and sometimes fatal hypersensitivity reactions have been products. Read full prescribing information section 5.1 before associated with ZIAGEN (abacavir sulfate). (5.1) prescribing ZIAGEN. (5.1) • Hypersensitivity to abacavir is a multi-organ clinical syndrome. • Lactic acidosis and severe hepatomegaly with steatosis have been (5.1) reported with the use of nucleoside analogues. (5.2) • Patients who carry the HLA-B*5701 allele are at high risk for • Immune reconstitution syndrome (5.3) and redistribution/accumulation
    [Show full text]
  • Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
    Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis Centers for Disease Control and Prevention Office of Infectious Diseases National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination June 2013 This document is accessible online at http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Suggested citation: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2013. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm Table of Contents Introduction 1 Methodology for Preparation of these Guidelines 2 The Role of Rifamycins in Tuberculosis Treatment 4 Managing Drug Interactions with Antivirals and Rifampin 5 Managing Drug Interactions with Antivirals and Rifabutin 9 Treatment of Latent TB Infection with Rifampin or Rifapentine 10 Treating Pregnant Women with Tuberculosis and HIV Co-infection 10 Treating Children with HIV-associated Tuberculosis 12 Co-treatment of Multidrug-resistant Tuberculosis and HIV 14 Limitations of these Guidelines 14 HIV-TB Drug Interaction Guideline Development Group 15 References 17 Table 1a. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults 21 Table 1b. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in children 22 Table 2a. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in adults 23 Table 2b. Recommendations for co-administering antiretroviral drugs with RIFAMPIN in children 25 Table 3. Recommendations for co-administering antiretroviral drugs with RIFABUTIN in adults 26 ii Introduction Worldwide, tuberculosis is the most common serious opportunistic infection among people with HIV infection.
    [Show full text]
  • Dolutegravir-Abacavir-Lamivudine (Triumeq)
    © National HIV Curriculum PDF created September 24, 2021, 7:23 pm Dolutegravir-Abacavir-Lamivudine (Triumeq) Table of Contents Dolutegravir-Abacavir-Lamivudine Triumeq Summary Drug Summary Key Clinical Trials Resistance Key Drug Interactions Drug Summary Dolutegravir-abacavir-lamivudine is a single-tablet regimen that is used primarily for treatment-naïve individuals. It has high potency, a relatively robust barrier to resistance (due to the dolutegravir component), and few drug interactions. It may be especially advantageous for individuals with renal insufficiency or risk factors for renal disease or osteoporosis, as it avoids the use of tenofovir DF. In certain treatment- experienced individuals, dolutegravir-abacavir-lamivudine may provide an option for switch or simplification of therapy. Abacavir can cause a life-threatening hypersensitivity reaction in individuals who are HLA-B*5701 positive; all patients need to undergo testing for HLA-B*5701 prior to receiving dolutegravir-abacavir- lamivudine and those who test positive for HLA-B*5701 should not receive this single tablet regimen. Dolutegravir blocks tubular secretion of creatinine and therefore causes a small increase in serum creatinine in the first 4 to 8 weeks of use; this increase is benign and does not indicate a change in true creatinine clearance. Key Clinical Trials In antiretroviral-naïve individuals, dolutegravir plus abacavir-lamivudine demonstrated superior virologic responses when compared with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine [SINGLE], with superiority largely driven by the greater tolerability of the dolutegravir plus abacavir-lamivudine regimen. In a comparison of 2 NRTIs plus either dolutegravir or raltegravir in treatment-naïve patients, virologic responses in the subset of patients who received dolutegravir plus abacavir-lamivudine were equivalent to those receiving raltegravir plus either tenofovir DF-emtricitabine or abacavir-lamivudine [SPRING-2].
    [Show full text]
  • Bictegravir-Tenofovir Alafenamide-Emtricitabine (Biktarvy)
    © National HIV Curriculum PDF created September 25, 2021, 12:10 pm Bictegravir-Tenofovir alafenamide-Emtricitabine (Biktarvy) Table of Contents Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy Summary Drug Summary Key Clinical Trials Key Drug Interactions Figures Drug Summary Bictegravir-tenofovir alafenamide-emtricitabine is a single-tablet regimen that is comprised of an integrase strand transfer inhibitor (bictegravir) combined with two nucleoside reverse transcriptase inhibitors (tenofovir alafenamide and emtricitabine). Bictegravir, which is not FDA-approved as an individual antiretroviral medication, has a high barrier to resistance, is well tolerated, and, extrapolating from the phase 3 data, has virologic efficacy comparable to dolutegravir. Bictegravir levels can be reduced with medications or oral supplement that contain polyvalent cations (e.g. Ca, Mg, Al, Fe). Bictegravir blocks tubular secretion of creatinine and typically raises serum creatinine by about 0.1 mg/dL, but without affecting renal glomerular function. Phase 3 trials in antiretroviral-naïve persons as well as switch trials in persons with virologic suppression have shown excellent efficacy with bictegravir-tenofovir alafenamide-emtricitabine. Available data suggest that bictegravir has a high genetic barrier to resistance. Key Clinical Trials In a phase 3 trial, 629 antiretroviral-naïve adults were randomized to receive bictegravir-tenofovir alafenamide-emtricitabine or dolutegravir-abacavir-lamivudine; after 48 weeks, there was no significant difference
    [Show full text]
  • Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3114-3 Program Step Therapy Medications Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate), efavirenz/emtricitabine/tenofovir disoproxil fumarate (generic Atripla) P&T Approval Date 9/2018, 3/2020, 3/2021 Effective Date 5/1/2021; Oxford only: 5/1/2021 1. Background: This program requires the provider to validate that the member is not an appropriate candidate for any of the following before providing coverage for Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate): Dovato (dolutegravir/lamivudine), Symfi or Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate), Triumeq (abacavir/dolutegravir/lamivudine), Isentress/Isentress HD (raltegravir) plus Cimduo (lamivudine/tenofovir disoproxil fumarate), Tivicay (dolutegravir) plus Cimduo (lamivudine/tenofovir disoproxil fumarate), or Juluca (dolutegravir/rilpivirine). For the treatment of HIV, antiretroviral regimens generally consist of three drugs –a two drug nucleoside reverse transcriptase inhibitor (NRTI) backbone in combination with a third drug from one of the following classes: integrase strand transfer inhibitor (INSTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI) with a pharmacokinetic (PK) enhancer. Data also support the use of the two-drug regimen, dolutegravir plus lamivudine, for initial treatment. Based on improved virologic outcomes and tolerability, INSTIs are recommended as first-line treatment options in most patients.1 Atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.2 2. Coverage Criteriaa: A. HIV 1. Atripla or generic Atripla will be approved based on both of the following: a.
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
    Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Pediatric Guidelines: Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at http://aidsinfo.nih.gov/content- files/lvguidelines/pediatricguidelines.pdf. Accessed (insert date) [include page numbers, table number, etc. if applicable] Use of antiretrovirals in pediatric patients is evolving rapidly. These guidelines are updated regularly to provide current information.The most recent information is available at http://aidsinfo.nih.gov. What’s New in the Pediatric Guidelines (Last updated April 14, 2020; last reviewed April 14, 2020) The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed previous versions of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection and revised the text and references. Key updates are summarized below. April 14, 2020 When to Initiate Therapy in Antiretroviral-Naive Children • The Panel now recommends rapid initiation of antiretroviral therapy (ART) for all children, not just those aged <1 year. Rapid initiation is defined as initiating therapy immediately or within days of HIV diagnosis. • Because the Panel no longer makes recommendations about when to initiate ART based on a child’s age (either <1 year of age or ≥1 year of age), Table A has been deleted and the data that support rapid initiation have been grouped by outcome (i.e., survival and health benefits, neurodevelopmental benefits, immune benefits, and viral reservoirs and viral suppression).
    [Show full text]
  • Package Leaflet: Information for the User Abacavir/Lamivudine 600 Mg
    Package leaflet: Information for the user Abacavir/Lamivudine 600 mg/300 mg film-coated tablets abacavir/lamivudine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IMPORTANT —Hypersensitivity reactions Abacavir/Lamivudine contains abacavir (which is also an active substance in medicines such as Trizivir, Triumeq and Ziagen). Some people who take abacavir may develop a hypersensitivity reaction (a serious allergic reaction), which can be life-threatening if they continue to take abacavir containing products. You must carefully read all the information under ‘Hypersensitivity reactions’ in the panel in Section 4. The Abacavir/Lamivudine pack includes an Alert Card, to remind you and medical staff about abacavir hypersensitivity. Detach this card and keep it with you at all times. What is in this leaflet 1. What Abacavir/Lamivudine is and what it is used for 2. What you need to know before you take Abacavir/Lamivudine 3. How to take Abacavir/Lamivudine 4. Possible side effects 5. How to store Abacavir/Lamivudine 6. Contents of the pack and other information 1. What Abacavir/Lamivudine is and what it is used for Abacavir/Lamivudine is used to treat HIV (human immunodeficiency virus) infection in adults, adolescents and in children weighing at least 25 kg.
    [Show full text]
  • Antiretroviral Drugs Impact Autophagy with Toxic Outcomes
    cells Review Antiretroviral Drugs Impact Autophagy with Toxic Outcomes Laura Cheney 1,*, John M. Barbaro 2 and Joan W. Berman 2,3 1 Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA 2 Department of Pathology, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA; [email protected] (J.M.B.); [email protected] (J.W.B.) 3 Department of Microbiology and Immunology, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA * Correspondence: [email protected]; Tel.: +1-718-904-2587 Abstract: Antiretroviral drugs have dramatically improved the morbidity and mortality of peo- ple living with HIV (PLWH). While current antiretroviral therapy (ART) regimens are generally well-tolerated, risks for side effects and toxicity remain as PLWH must take life-long medications. Antiretroviral drugs impact autophagy, an intracellular proteolytic process that eliminates debris and foreign material, provides nutrients for metabolism, and performs quality control to maintain cell homeostasis. Toxicity and adverse events associated with antiretrovirals may be due, in part, to their impacts on autophagy. A more complete understanding of the effects on autophagy is essential for developing antiretroviral drugs with decreased off target effects, meaning those unrelated to viral suppression, to minimize toxicity for PLWH. This review summarizes the findings and highlights the gaps in our knowledge of the impacts of antiretroviral drugs on autophagy. Keywords: HIV; antiretroviral drugs; side effects; toxicity; autophagy; mitophagy; mitochondria; Citation: Cheney, L.; Barbaro, J.M.; ER stress Berman, J.W.
    [Show full text]
  • The HIV Protease Inhibitors Nelfinavir and Saquinavir, but Not a Variety Of
    Antiviral Therapy 10:215–223 The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function Marco Piccinini1, Maria T Rinaudo1*, Annalisa Anselmino1, Barbara Buccinnà1, Cristina Ramondetti1, Antonio Dematteis1, Emanuela Ricotti 2, Lucia Palmisano3, Michael Mostert2 and Pier-Angelo Tovo2 1Department of Medicine and Experimental Oncology and 2Department of Paediatric Sciences, University of Turin, Turin, Italy 3Istituto Superiore di Sanità, Rome, Italy *Corresponding author: Tel: +39 011 670 5303 Fax: +39 011 670 5311; E-mail: [email protected] Background: In HIV-infected patients some clinical and drugs at different concentrations. Intracellular protea- immunological benefits of antiretroviral therapy, which some proteolytic activity was evaluated by searching for frequently include a combination of HIV protease inhibitors ubiquitin-tagged proteins in HL60 cells incubated with (PIs) and reverse transcriptase inhibitors (RTIs), cannot be and without the drugs. solely explained by the drugs’ action on viral enzymes. Results: At therapeutic dosages, nelfinavir and saquinavir Proteasomes constitute the central protease of the ubiq- inhibited proteasome peptidase activity and caused uitin ATP-dependent pathway involved in many cellular intracellular accumulation of polyubiquitinated proteins, processes, as well as in HIV maturation and aggressiveness. a hallmark of proteasome proteolytic inhibition in vivo; Objective: To explore whether the PIs nelfinavir and the RTIs failed to evoke either effect. saquinavir and the RTIs abacavir, nevirapine, delavirdine, Conclusion: Proteasomes are targeted by the two PIs but stavudine and didanosine affect proteasome function in not the RTIs. Therefore, in HIV-infected patients the vitro and in vivo. beneficial effect of a therapy including one of the two Methods: Peptidase activity of purified human 26S and PIs should partly rely on inhibition of host proteasome 20S proteasomes was assayed with and without the function.
    [Show full text]
  • Therapeutic Guidelines for Antiretroviral (ARV) Treatment of Adult HIV Infection September 2015
    Therapeutic Guidelines for Antiretroviral (ARV) Treatment of Adult HIV Infection September 2015 Prepared by J Montaner (editor), S Guillemi and M Harris (co-editors) on behalf of the Committee for Drug Evaluation and Therapy, British Columbia Centre for Excellence in HIV/AIDS The BC-CfE Therapeutic Guidelines have remained generally consistent but not identical with the IAS-USA Guidelines since 1996. The current Guidelines are consistent with those published by H.F. Günthard et al. in 2014 (Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society–USA Panel. JAMA 2014; 312(4):410-425). However, the reader should be aware that the use of antiretroviral drugs for the treatment of HIV infection within the BC-CfE programs is exclusively guided by the 2015 Guidelines as outlined here. BC-CfE 2015 ARV Guidelines Page: 2 Committee for Drug Evaluation and Therapy of the BC Centre for Excellence in HIV/AIDS Co-chairs Rolando Barrios Val Montessori Committee Members Linda Akagi Silvia Guillemi Marianne Harris Robert Hogg Mark Hull Deborah Money David Moore Peter Phillips Neora Pick BC-CfE 2015 ARV Guidelines Page: 3 TABLE OF CONTENTS Glossary of abbreviations……………………………………………………………………….….…………….5 I. Summary…………………………………………….…………………………………………………….……...………7 II. Introduction…………………………………………………………………………………………………..……….…9 III. When to start…………………………………………………………………………………………………………..10 A. Recommendations ……………………………………………………………………………………………10 B. Evidence…………………………………………………………………………………………………….……..10
    [Show full text]
  • Nelfinavir Use in Ghana
    Nelfinavir: Where are we now? Experience in Ghana Delese Mimi Darko Head, Drug Evaluation and Registration Food and Drugs Board 13th ICDRA, September,2008 Berne, Switzerland AND DRUGS B D OA O R O D F FDB G H A N A Outline • HIV/AIDS – The Ghanaian Situation • Pharmacovigilance System in Ghana • Brief on Nelfinavir Use • Brands Registered by FDB • Safety Issues with Nelfinavir • Future Actions • Conclusions AND DRUGS B D OA O R ICDRA Bern 2008 O D 2 F FDB Ghana’s Nelfinavir Experience G H A N A Tropical Climate Estimated population 22million AND DRUGS B D OA O R ICDRA Bern 2008 O D 3 F FDB Ghana’s Nelfinavir Experience G H A N A HIV/AIDS Situation in Ghana 1 • National HIV sero-prevalence 1.9 (2008) • Prevalence rural being 1.7% and urban 2.3% • 264,481 people living with HIV/AIDS, with 110,666 males and 153,851 females • 16,974 children living with HIV • 2959 annually HIV positive births • Cumulative AIDS deaths of 180,889 (2007) • 12,315 HIV/AIDS patients on ART AND DRUGS B D OA O R ICDRA Bern 2008 O D 4 F FDB Ghana’s Nelfinavir Experience G H A N A HIV/AIDS Situation in Ghana 2 • VCT Services – 161,903 services received • 10% of tested positive (71% women) • PMTCT – 104,045 pregnant women screened • 3.2% tested positive AND DRUGS B D OA O R O D F FDB G H A N A ART Provision Sites • 95 centres distributed throughout the country (public, private and not-for-profit health institutions) • ART provision started in four pilot facilities • Gradual roll out nationally • Four pilot sites – Atua Govt Hospital, St.
    [Show full text]